Cadila Pharma Develops World’s First Novel 3-Dose Vaccine Against Rabies

Share Us

771
Cadila Pharma Develops World’s First Novel 3-Dose Vaccine Against Rabies
11 Apr 2022
4 min read

News Synopsis

Cadila Pharmaceuticals, a pharmaceutical company has announced that it has developed the world’s first novel three-dose vaccine against rabies. 

The triple-dose vaccine, dubbed "ThRabis," is a recombinant nano-particle based G protein vaccine made using virus-like particle technology, the company said in a press release, with a short three-dose schedule. He added that it would last for a week.

CMD Rajiv Modi of Cadila Pharmaceuticals said at the launch of the new vaccine, the new vaccine will be a game-changer as all existing rabies vaccines require five injections every 28 days.

It is estimated that  59,000 animal bite victims die each year from rabies worldwide, primarily in Asia and Africa. According to a press release, more than 20,000 people have died in India alone, primarily because the vaccines available to many animal bite victims have not been fully completed.

The vaccine will be launched in 11 states in its first phase. The company representatives would contact nearly 6,000 doctors as part of their awareness campaign in these states. The price of the vial is Rs 750 while the cost of treatment, comprising three doses, would come to Rs 2,145.

TWN In-Focus